Oral Cavity Calprotectin and Lactoferrin Levels in Relation to Radiotherapy

Background: Lactoferrin, an iron-binding glycoprotein, and calprotectin, a calcium binding protein, are sensitive markers of inflammation and their fecal levels increase during radiotherapy of prostate cancer patients. With this background, we analyzed mouthrinse calprotectin and lactoferrin levels of head- and neck-cancer patients before, during and after radiotherapy. Methods: Twenty cancer patients (mean age 55.85 ± 15.01, 80% male), who had been planned to undergo radiotherapy to the head and neck area, were included in this study. Mouthrinse samples were collected before radiotherapy, at the 3rd and 6th weeks of radiotherapy and 4 weeks after the radiotherapy. Mouthrinse samples were analyzed for calprotectin and lactoferrin using commercial ELISA kits. Results: Calprotectin levels increased significantly during radiotherapy (p = 0.022). Both markers, lactoferrin (p = 0.011) and calprotectin (p = 0.006), decreased significantly after the treatment. Conclusions: Present study results may suggest that the elevations in calprotectin and lactoferrin levels during radiotherapy reflect the increased and emerging inflammatory environment in the oral cavity, thus may increase the risk of periodontal disease initiation or progression.laktoferriinia, sekä pään ja kaulan alueen syöpää ja sädehoitoa. Kalprotektiini on kalsiumia ja sinkkiä sitova proteiini, joka koostuu kahdesta osasta (S100A8 ja S100A9). Sitä löytyy pääasiassa neutrofiileistä. Laktoferriini on rautaa sitova transferriiniperheeseen kuuluva proteiini. Sitä löytyy elimistön nesteistä, esimerkiksi syljestä. Pään ja kaulan alueen syövillä tarkoitetaan pahanlaatuisia kasvaimia, joiden yleinen hoitomuoto on sädehoito. Tutkimuksen tarkoituksena oli tutkia kalprotektiinin ja laktoferriinin pitosuuksia suuhuuhteesta pään ja kaulan alueen syöpäpotilailla ennen sädehoitoa, sen aikana ja hoidon jälkeen. Tutkimukseen osallistui 20 pään ja kaulan alueen syöpäpotilasta, jotka hoidettiin sädehoidolla. Suuhuuhdenäytteet kerättiin ennen sädehoitoa, sen aikana (kolmannen ja kuudennen viikon kohdalla) ja neljä viikkoa hoidon päättymisen jälkeen. Suuhuuhteista analysoitiin kalprotektiinin ja laktoferriinin pitoisuudet ELISA kittien avulla. Kalprotektiinin pitoisuus nousi tilastollisesti merkitsevästi sädehoidon aikana (p = 0.022). Molempien, kalprotektiinin (p = 0.006) ja laktoferriinin (p = 0.011), pitoisuudet laskivat tilastollisesti merkitsevästi sädehoidon päätyttyä. Koska sädehoidon aikana markkerien pitoisuudet suuhuuhteessa nousivat, voimme päätellä, että sädehoito aiheuttaa elimistöön tulehduksellisen tilan. Kuitenkin markkereiden pitoisuudet laskivat aloitustasolle hoidon päätyttyä, joten kyseessä on tilapäinen tulehdustila

Oral Cavity Calprotectin and Lactoferrin Levels in Relation to Radiotherapy

Background: Lactoferrin, an iron-binding glycoprotein, and calprotectin, a calcium binding protein, are sensitive markers of inflammation and their fecal levels increase during radiotherapy of prostate cancer patients. With this background, we analyzed mouthrinse calprotectin and lactoferrin levels of head- and neck-cancer patients before, during and after radiotherapy. Methods: Twenty cancer patients (mean age 55.85 ± 15.01, 80% male), who had been planned to undergo radiotherapy to the head and neck area, were included in this study. Mouthrinse samples were collected before radiotherapy, at the 3rd and 6th weeks of radiotherapy and 4 weeks after the radiotherapy. Mouthrinse samples were analyzed for calprotectin and lactoferrin using commercial ELISA kits. Results: Calprotectin levels increased significantly during radiotherapy (p = 0.022). Both markers, lactoferrin (p = 0.011) and calprotectin (p = 0.006), decreased significantly after the treatment. Conclusions: Present study results may suggest that the elevations in calprotectin and lactoferrin levels during radiotherapy reflect the increased and emerging inflammatory environment in the oral cavity, thus may increase the risk of periodontal disease initiation or progression

Oral Cavity Calprotectin and Lactoferrin Levels in Relation to Radiotherapy

Background: Lactoferrin, an iron-binding glycoprotein, and calprotectin, a calcium binding protein, are sensitive markers of inflammation and their fecal levels increase during radiotherapy of prostate cancer patients. With this background, we analyzed mouthrinse calprotectin and lactoferrin levels of head- and neck-cancer patients before, during and after radiotherapy. Methods: Twenty cancer patients (mean age 55.85 ± 15.01, 80% male), who had been planned to undergo radiotherapy to the head and neck area, were included in this study. Mouthrinse samples were collected before radiotherapy, at the 3rd and 6th weeks of radiotherapy and 4 weeks after the radiotherapy. Mouthrinse samples were analyzed for calprotectin and lactoferrin using commercial ELISA kits. Results: Calprotectin levels increased significantly during radiotherapy (p = 0.022). Both markers, lactoferrin (p = 0.011) and calprotectin (p = 0.006), decreased significantly after the treatment. Conclusions: Present study results may suggest that the elevations in calprotectin and lactoferrin levels during radiotherapy reflect the increased and emerging inflammatory environment in the oral cavity, thus may increase the risk of periodontal disease initiation or progression

Oral Cavity Calprotectin and Lactoferrin Levels in Relation to Radiotherapy

Background: Lactoferrin, an iron-binding glycoprotein, and calprotectin, a calcium binding protein, are sensitive markers of inflammation and their fecal levels increase during radiotherapy of prostate cancer patients. With this background, we analyzed mouthrinse calprotectin and lactoferrin levels of head- and neck-cancer patients before, during and after radiotherapy.Methods: Twenty cancer patients (mean age 55.85 ± 15.01, 80% male), who had been planned to undergo radiotherapy to the head and neck area, were included in this study. Mouthrinse samples were collected before radiotherapy, at the 3rd and 6th weeks of radiotherapy and 4 weeks after the radiotherapy. Mouthrinse samples were analyzed for calprotectin and lactoferrin using commercial ELISA kits.Results: Calprotectin levels increased significantly during radiotherapy (p = 0.022). Both markers, lactoferrin (p = 0.011) and calprotectin (p = 0.006), decreased significantly after the treatment.Conclusions: Present study results may suggest that the elevations in calprotectin and lactoferrin levels during radiotherapy reflect the increased and emerging inflammatory environment in the oral cavity, thus may increase the risk of periodontal disease initiation or progression.</p

Oral Cavity Calprotectin and Lactoferrin Levels in Relation to Radiotherapy

Background: Lactoferrin, an iron-binding glycoprotein, and calprotectin, a calcium binding protein, are sensitive markers of inflammation and their fecal levels increase during radiotherapy of prostate cancer patients. With this background, we analyzed mouthrinse calprotectin and lactoferrin levels of head- and neck-cancer patients before, during and after radiotherapy. Methods: Twenty cancer patients (mean age 55.85 &plusmn; 15.01, 80% male), who had been planned to undergo radiotherapy to the head and neck area, were included in this study. Mouthrinse samples were collected before radiotherapy, at the 3rd and 6th weeks of radiotherapy and 4 weeks after the radiotherapy. Mouthrinse samples were analyzed for calprotectin and lactoferrin using commercial ELISA kits. Results: Calprotectin levels increased significantly during radiotherapy (p = 0.022). Both markers, lactoferrin (p = 0.011) and calprotectin (p = 0.006), decreased significantly after the treatment. Conclusions: Present study results may suggest that the elevations in calprotectin and lactoferrin levels during radiotherapy reflect the increased and emerging inflammatory environment in the oral cavity, thus may increase the risk of periodontal disease initiation or progression